Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug
AI Summary
Cingulate reported a Q2 loss and plans to resubmit to the FDA for its ADHD drug approval. The company is navigating regulatory challenges in the health sector.
Related Articles
Hammack Says the Fed Needs to 'Act Now' on Inflation
Bloomberg —
FGN Savings Bond: DMO raises N5.86 billion as investor demand cools in August
Nairametrics Nigeria —
Salesforce’s stock gets a boost as J.P. Morgan says AI fears are overblown
MarketWatch —
Fed's Hammack Questions Whether Inflation Slowdown Will Continue
Bloomberg —
FG re-opens 3 bonds valued at N1.1trn for subscription for Aug
Vanguard Nigeria —
Why The Fed Will Raise Rates In September Despite Cooler CPI
Seeking Alpha —